Markets believe AstraZeneca can continue to deliver strong double-digit growth in 2022, but will the pharma giant’s outlook meet expectations this week?
The Anglo-Swedish drugmaker worked with Oxford to develop one of the first COVID-19 vaccines authorised for widespread use. AstraZeneca said it hopes to cut the time needed to produce large amounts of any new vaccine to between six and nine months